source
- Astellas signs up to $1.34 billion option deal for Audax's DAX-044 immuno-oncology candidateAstellas Pharma announced it will pay up to $1.34 billion for an exclusive option to license Audax Biosciences' investigational antibody-cytokine fusion, DAX-044. The agreement includes an undiscl…
- Biogen sees continued revenue growth and pipeline readouts, M&A not essential, CEO saysBiogen reported third‑quarter earnings, marking a third straight quarter of revenue growth driven by its marketed products. The increase stemmed from higher sales of the Alzheimer’s therapy Leqemb…